NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)

PHASE3RecruitingINTERVENTIONAL
Enrollment

609

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2027

Conditions
Resectable Pancreatic CancerNeoadjuvant ChemotherapyEffects of Chemotherapy
Interventions
DRUG

Folfirinox

The primary aim of this trial was to investigate whether six cycles of preoperative mFOLFIRINOX followed by six cycles of postoperative mFOLFIRINOX improved the overall survival rate by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX.

Trial Locations (2)

06591

RECRUITING

Department of Internal Medicine, Seoul St. Mary's Hospital, Catholic University College of Medicine, Seoul

110-744

RECRUITING

Department of Surgery, Seoul National University College of Medicine, Seoul

All Listed Sponsors
collaborator

Seoul National University Bundang Hospital

OTHER

collaborator

SMG-SNU Boramae Medical Center

OTHER

collaborator

Gangnam Severance Hospital

OTHER

collaborator

Seoul St. Mary's Hospital

OTHER

lead

Seoul National University Hospital

OTHER